In the company's eight-year clinical study, which enrolled 8,302 cancer patients with varying disease type and severity, Escozine was found to have a near 90 percent success rate in improving quality of life, which included everything from decreased pain to increased survival rates. But the company acknowledged that the study was not peer-reviewed, and the results of their trial are not accepted by the American standards of science.
The Good and Great thing about Escozine® is "Not" a Vaccine like those Non FDA Approved by JNJ BNTX NVAX yet...and I'm One of those MultiMillions who will "Not" dare get Injected.
QNTA @ current pps is a Fortune builder for a LongBagholder.